Literature DB >> 27779277

Persistent gastro-oesophageal reflux symptoms despite proton pump inhibitor therapy.

Daphne Ang1, Choon How How2, Tiing Leong Ang1.   

Abstract

About one-third of patients with suspected gastro-oesophageal reflux disease (GERD) do not respond symptomatically to proton pump inhibitors (PPIs). Many of these patients do not suffer from GERD, but may have underlying functional heartburn or atypical chest pain. Other causes of failure to respond to PPIs include inadequate acid suppression, non-acid reflux, oesophageal hypersensitivity, oesophageal dysmotility and psychological comorbidities. Functional oesophageal tests can exclude cardiac and structural causes, as well as help to confi rm or exclude GERD. The use of PPIs should only be continued in the presence of acid reflux or oesophageal hypersensitivity for acid reflux-related events that is proven on functional oesophageal tests. Copyright: © Singapore Medical Association.

Entities:  

Keywords:  GERD; acid reflux; non-acid reflux; pH-impedance; reflux hypersensitivity

Mesh:

Substances:

Year:  2016        PMID: 27779277      PMCID: PMC5075954          DOI: 10.11622/smedj.2016167

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  44 in total

Review 1.  Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors.

Authors:  Daniel Sifrim; Frank Zerbib
Journal:  Gut       Date:  2012-06-08       Impact factor: 23.059

2.  The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.

Authors:  Fabio Pace; Marina Pace
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-08       Impact factor: 3.869

Review 3.  Refractory gastroesophageal reflux disease: advances and treatment.

Authors:  Fehmi Ates; David O Francis; Michael F Vaezi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-04-19       Impact factor: 3.869

Review 4.  Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease.

Authors:  G E Boeckxstaens; A Smout
Journal:  Aliment Pharmacol Ther       Date:  2010-05-18       Impact factor: 8.171

Review 5.  Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease.

Authors:  A Becher; H El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2011-07-20       Impact factor: 8.171

6.  Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; C Wilcock; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-10       Impact factor: 2.423

Review 7.  The role of proton pump inhibitors in gastro-oesophageal reflux disease.

Authors:  Roy Dekel; Chad Morse; Ronnie Fass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care.

Authors:  R Jones; O Junghard; J Dent; N Vakil; K Halling; B Wernersson; T Lind
Journal:  Aliment Pharmacol Ther       Date:  2009-09-08       Impact factor: 8.171

Review 9.  Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Authors:  Kirsten E Sigterman; Bart van Pinxteren; Peter A Bonis; Joseph Lau; Mattijs E Numans
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

10.  Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded.

Authors:  Ram Dickman; Mona Boaz; Shoshanna Aizic; Zaza Beniashvili; Ronnie Fass; Yaron Niv
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

View more
  4 in total

1.  Banhasasim-Tang Treatment Reduces the Severity of Esophageal Mucosal Ulcer on Chronic Acid Reflux Esophagitis in Rats.

Authors:  Mi-Rae Shin; Bu-Il Seo; Chang Gue Son; Seong-Soo Roh; Hyo-Jin An
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

2.  Anti-Heartburn Effects of Sugar Cane Flour: A Double-Blind, Randomized, Placebo-Controlled Study.

Authors:  Jeffrey M Beckett; Neeraj K Singh; Jehan Phillips; Krishnakumar Kalpurath; Kent Taylor; Roger A Stanley; Rajaraman D Eri
Journal:  Nutrients       Date:  2020-06-18       Impact factor: 5.717

3.  Profile of the Change in Depression during Proton-Pump Inhibitor Therapy in Patients with Gastroesophageal Reflux Disease: Influence of the Mucosal Break.

Authors:  Chia-Liang Wu; Chien-Lin Chen; Shu-Hui Wen
Journal:  Int J Environ Res Public Health       Date:  2021-06-02       Impact factor: 3.390

4.  Evaluation and Validation of the Modified Reflux Symptom Questionnaire-Electronic Diary in Patients With Persistent Gastroesophageal Reflux Disease.

Authors:  David A Andrae; Jennifer Hanlon; Mary Lynn Cala; Kayla Scippa; Christina Graham; Brooke Witherspoon; James Z Shao; David Reasner
Journal:  Clin Transl Gastroenterol       Date:  2020-01       Impact factor: 4.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.